These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cell-cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis. Wang S; Kim JH; Moon KC; Hong HK; Lee HS Am J Kidney Dis; 2004 Jan; 43(1):19-27. PubMed ID: 14712423 [TBL] [Abstract][Full Text] [Related]
8. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Shankland SJ; Floege J; Thomas SE; Nangaku M; Hugo C; Pippin J; Henne K; Hockenberry DM; Johnson RJ; Couser WG Kidney Int; 1997 Aug; 52(2):404-13. PubMed ID: 9263996 [TBL] [Abstract][Full Text] [Related]
9. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy. Yang Y; Gubler MC; Beaufils H Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471 [TBL] [Abstract][Full Text] [Related]
10. Phenotypic characteristics and cyclin-dependent kinase inhibitors repression in hyperplastic epithelial pathology in idiopathic focal segmental glomerulosclerosis. Nagata M; Horita S; Shu Y; Shibata S; Hattori M; Ito K; Watanabe T Lab Invest; 2000 Jun; 80(6):869-80. PubMed ID: 10879738 [TBL] [Abstract][Full Text] [Related]
11. The morphological characteristics and expression of cell cycle regulatory proteins in cellular variants of idiopathic focal segmental glomerulosclerosis. Wang SX; Liu G; Zou WZ; Wang HY Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):145-9. PubMed ID: 15100731 [TBL] [Abstract][Full Text] [Related]
13. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671 [TBL] [Abstract][Full Text] [Related]
14. Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Shankland SJ; Hugo C; Coats SR; Nangaku M; Pichler RH; Gordon KL; Pippin J; Roberts JM; Couser WG; Johnson RJ Kidney Int; 1996 Oct; 50(4):1230-9. PubMed ID: 8887282 [TBL] [Abstract][Full Text] [Related]
15. New functional activities for the p21 family of CDK inhibitors. LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657 [TBL] [Abstract][Full Text] [Related]
16. Contrasting roles of p57(KIP2) and p21(WAF1/CIP1/SDI1) in transplanted human and bovine adrenocortical cells. Thomas M; Popnikolov NK; Scott C; Smith JR; Hornsby PJ Exp Cell Res; 2001 May; 266(1):106-13. PubMed ID: 11339829 [TBL] [Abstract][Full Text] [Related]
17. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Lee MH; Reynisdóttir I; Massagué J Genes Dev; 1995 Mar; 9(6):639-49. PubMed ID: 7729683 [TBL] [Abstract][Full Text] [Related]
18. Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Combs HL; Shankland SJ; Setzer SV; Hudkins KL; Alpers CE Kidney Int; 1998 Apr; 53(4):892-6. PubMed ID: 9551395 [TBL] [Abstract][Full Text] [Related]
20. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]